Agonistic antibody with a unique mechanism of action - regulation of T-Cell homeostasis
Our lead candidate has demonstrated proof of clinical efficacy in patients with Psoriatic Arthritis and will also be used for commencing a phase 2a clinical trial in patients with Ulcerative Colitis. This novel therapeutic antibody activates a natural cell death signaling in chronically proliferating late-stage activated T cells through a novel immune-check-point molecule, without compromising normal immune function.
Proprietary ADC-linker and biosuperior ADCs
The successful development of our proprietary linker-payload platform and a tumor antigen targeting platform allows for the generation of several biobetter/biosuperior antibody drug conjugates against various cancers.
Clinical-stage drug candidates for the treatment of several inflammatory/autoimmune diseases and cancers
Fully-integrated discovery and development of antibody-based therapeutics
Diverse product pipeline for various novel and validated therapeutic targets
Highly collaborative team of scientists with a proven capability to pioneer advanced technology platforms
Professional management team fostering a unique corporate culture focusing on innovation
Open to worldwide collaborative growth opportunities and strategic partnershipsLearn more